Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GCS-100 with R-ICE in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2008-004087-40Phase 2Unknown
- Sponsor
- Prospect Therapeutics
- Start
- Oct 2008
- Countries
- 1
01
Overview
Phase 2, single-arm trial of GCS-100 in diffuse large B-cell lymphoma (DLBCL), sponsored by Prospect Therapeutics. Primary endpoint: Overall response rate (CR + PR). Status: unknown.
02
Drugs
GCS-100
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-004087-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004087-40.